Company intelligence / Profile preview

Tibet Ganlu Tibetan Medicine

Ownership: Private
Development stage: Other

Overview

The company has at least one approved product ("Cuitang Pills") for the common cold on the Chinese market since October 2020. It focuses on traditional Tibetan herbal medicines with some clinical and ethnopharmacological research published. No advanced Western-style clinical trial data available publicly.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Herbal medicine
Industry: Biotech

Drug pipeline

24 assets

Renqing Changjue

Unknown

23 more assets in the full pipeline.

Request access →

Partnerships

None publicly disclosed

Beyond the preview

Go deeper on Tibet Ganlu Tibetan Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tibet Ganlu Tibetan Medicine.

Explore the full profile